What is NeoGenomics, Inc.'s earnings per share (EPS)?

NeoGenomics, Inc. (NEO) reported diluted earnings per share of -$0.84 for fiscal year 2025. This represents a -35.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NeoGenomics, Inc. (NEO) Financials

NEO

Trailing 12 months to June 30, 2026

Revenue $766.3M +11.2% YoY

Net Income -$51.9M +50.3% YoY

EPS (Diluted) -$0.39 +51.9% YoY

Free Cash Flow -$7.4M +61.6% YoY

Market Cap $2.2B as of Sep 12, 2026

Price / Sales 2.9x on $766.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 2.8x on $785.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 28, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NEO SEC filings page.

NeoGenomics, Inc. (NEO) reported $766.3M in revenue over the twelve months to Jun 30, 2026, up 11.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NEO FY2025 2026-08-29

Gross-profit expansion is being absorbed by fixed overhead and reinvestment before it reaches durable earnings.

Gross margin widened from 36.9% to 43.2% across the reported period, yet operating margin remained negative, showing that improved unit economics have not covered the broader cost base. Operating cash flow turned positive in FY2024 and FY2025 while net income stayed negative, but capital spending kept free cash flow negative; reported cash generation and economic reinvestment needs still diverge.

Debt declined from $538M to $342M across the reported period. Total liabilities also fell to $523M, but equity declined to $837M; the balance-sheet improvement therefore reflects both lower obligations and a shrinking capital base, rather than simple strengthening.

FY2025 operating cash flow was $5M, while capital expenditures were $27M. That gap kept free cash flow at -$22M even as revenue reached $727M, indicating that the operating model still requires reinvestment beyond internally generated cash.

Financial Health Signals

Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of NeoGenomics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

NeoGenomics, Inc. has an operating margin of -15.9%, meaning the company loses $16 on every $100 of revenue. This results in a profitability score of 30/100. This is down from -13.9% the prior year.

Growth

NeoGenomics, Inc.'s revenue grew 10.1% year-over-year to $727.3M, a solid pace of expansion. This earns a growth score of 67/100.

Leverage

NeoGenomics, Inc. has a moderate D/E ratio of 0.41. This balance of debt and equity financing earns a leverage score of 64/100.

Liquidity

With a current ratio of 4.26, NeoGenomics, Inc. holds $4.26 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.

Cash Flow

While NeoGenomics, Inc. generated $5.2M in operating cash flow, capex of $27.0M consumed most of it, leaving -$21.8M in free cash flow. This results in a low score of 17/100, reflecting heavy capital investment rather than weak cash generation.

Returns

NeoGenomics, Inc. posts a -12.9% return on equity (ROE), meaning it loses $13 for every $100 of shareholders' equity. This results in a returns score of 39/100. This is down from -8.8% the prior year.

Altman Z-Score Grey Zone

2.61

NeoGenomics, Inc. scores 2.61, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($523.3M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

NeoGenomics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

NeoGenomics, Inc. reported a net loss of $108.0M while generating $5.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

NeoGenomics, Inc. reported an operating loss of $115.9M against $3.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$201.7M

YoY+11.2%

QoQ+8.0%

5Y CAGR+10.6%

10Y CAGR+12.3%

NeoGenomics, Inc. generated $201.7M in revenue in Q2 2026. This represents an increase of 11.2% from the same quarter a year earlier. Against the prior quarter it is up 8.0%.

EBITDA

$6.4M

YoY+121.2%

QoQ+452.2%

NeoGenomics, Inc.'s EBITDA was $6.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 121.2% from the same quarter a year earlier. Against the prior quarter it is up 452.2%.

Net Income

$2.2M

YoY+105.0%

QoQ+113.1%

5Y CAGR-50.6%

10Y CAGR+18.4%

NeoGenomics, Inc. reported $2.2M in net income in Q2 2026. This represents an increase of 105.0% from the same quarter a year earlier. Against the prior quarter it is up 113.1%.

EPS (Diluted)

$0.02

YoY+105.7%

QoQ+115.4%

5Y CAGR-49.2%

NeoGenomics, Inc. earned $0.02 per diluted share (EPS) in Q2 2026. This represents an increase of 105.7% from the same quarter a year earlier. Against the prior quarter it is up 115.4%.

Cash & Balance Sheet

Free Cash Flow

$11.7M

YoY-16.2%

QoQ+189.4%

10Y CAGR+16.2%

NeoGenomics, Inc. generated $11.7M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 16.2% from the same quarter a year earlier. Against the prior quarter it is up 189.4%.

Cash & Debt

$145.5M

YoY-5.9%

QoQ-0.4%

5Y CAGR-17.0%

10Y CAGR+20.9%

NeoGenomics, Inc. held $145.5M in cash against $374.2M in long-term debt as of Q2 2026.

Shares Outstanding

128M

YoY-0.5%

QoQ-1.3%

5Y CAGR+0.9%

10Y CAGR+5.1%

NeoGenomics, Inc. had 128M shares outstanding in Q2 2026. This represents a decrease of 0.5% from the same quarter a year earlier. Against the prior quarter it is down 1.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

45.6%

YoY+3.0pp

QoQ+2.2pp

5Y change+2.0pp

10Y change+0.3pp

NeoGenomics, Inc.'s gross margin was 45.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.

Operating Margin

-4.9%

YoY+21.4pp

QoQ+4.9pp

5Y change+13.5pp

NeoGenomics, Inc.'s operating margin was -4.9% in Q2 2026, reflecting core business profitability. This is up 21.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.9 percentage points.

Net Margin

1.1%

YoY+26.0pp

QoQ+10.3pp

5Y change-61.2pp

10Y change+0.5pp

NeoGenomics, Inc.'s net profit margin was 1.1% in Q2 2026, showing the share of revenue converted to profit. This is up 26.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.3 percentage points.

Return on Equity

0.3%

YoY+5.6pp

QoQ+2.3pp

5Y change-6.3pp

10Y change+0.1pp

NeoGenomics, Inc.'s ROE was 0.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.

Capital Allocation

R&D Spending

$10.8M

YoY+19.3%

QoQ+12.9%

5Y CAGR+25.2%

NeoGenomics, Inc. invested $10.8M in research and development in Q2 2026. This represents an increase of 19.3% from the same quarter a year earlier. Against the prior quarter it is up 12.9%.

Capital Expenditures

$8.2M

YoY+30.0%

QoQ+64.4%

5Y CAGR-17.4%

10Y CAGR+13.0%

NeoGenomics, Inc. invested $8.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 30.0% from the same quarter a year earlier. Against the prior quarter it is up 64.4%.

Share Buybacks

Not reported for Q2 2026.

NEO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NEO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$766.3M	$727.3M+10.1%	$660.6M+11.6%	$591.6M+16.1%	$509.7M+5.2%	$484.3M+9.0%	$444.4M+8.7%	$408.8M+47.7%	$276.7M+15.2%	$240.3M+3.6%	$231.8M+4536.2%	$5.0M0.0%	$5.0M0.0%	$5.0M0.0%	$5.0M-88.5%	$43.5M
Cost of Revenue	$429.8M	$413.0M+11.5%	$370.5M+6.8%	$347.0M+7.8%	$321.8M+8.3%	$297.3M+15.0%	$258.6M+22.0%	$212.0M+41.8%	$149.5M+8.1%	$138.3M+3.4%	$133.7M	N/A	N/A	N/A	N/A	N/A
Gross Profit	$336.5M	$314.3M+8.3%	$290.1M+18.6%	$244.6M+30.2%	$187.9M+0.4%	$187.1M+0.6%	$185.9M-5.6%	$196.8M+54.7%	$127.3M+24.8%	$102.0M+3.9%	$98.1M	N/A	N/A	N/A	N/A	$19.4M
R&D Expenses	$38.2M	$37.1M+19.0%	$31.2M+14.1%	$27.3M-9.9%	$30.3M+38.6%	$21.9M+165.8%	$8.2M-3.0%	$8.5M+182.8%	$3.0M-17.5%	$3.6M-21.8%	$4.6M+10.7%	$4.2M+56.1%	$2.7M+10.2%	$2.4M+7.0%	$2.3M+320.1%	$543K
SG&A Expenses	$262.7M	$273.3M+5.2%	$259.7M+6.8%	$243.1M-0.1%	$243.4M+9.9%	$221.3M+53.9%	$143.8M+12.3%	$128.0M+50.9%	$84.8M+20.6%	$70.4M+10.1%	$63.9M+90.1%	$33.6M+41.3%	$23.8M+36.9%	$17.4M+9.8%	$15.8M+28.5%	$12.3M
Operating Income	-$68.4M	-$115.9M-25.8%	-$92.1M+14.5%	-$107.7M+31.6%	-$157.6M-32.7%	-$118.8M-748.7%	-$14.0M-207.6%	$13.0M+29.5%	$10.0M+246.0%	$2.9M+34.7%	$2.2M+138.2%	-$5.6M-354.1%	$2.2M-30.1%	$3.2M+162.1%	$1.2M+396.1%	-$409K
EBITDA	N/A	-$48.1M-145.7%	-$19.6M+44.4%	-$35.2M+60.1%	-$88.2M-34.8%	-$65.4M-649.0%	$11.9M-64.3%	$33.4M+29.1%	$25.8M+39.7%	$18.5M+2.2%	$18.1M+1552.2%	$1.1M-85.5%	$7.6M+2.7%	$7.4M+51.9%	$4.8M+189.2%	$1.7M
Interest Expense	$2.6M	$3.8M-43.3%	$6.6M-4.2%	$6.9M-8.9%	$7.6M-7.8%	$8.2M+17.1%	$7.0M+89.0%	$3.7M-40.4%	$6.2M+12.5%	$5.5M-44.6%	$10.0M+1070.7%	$854K-13.3%	$985K-0.4%	$989K-13.7%	$1.1M+49.2%	$768K
Income Tax	-$2.7M	-$2.2M-15.1%	-$1.9M+78.7%	-$9.1M+39.5%	-$15.1M-124.3%	-$6.7M+63.1%	-$18.2M-318.0%	-$4.4M-468.3%	$1.2M+152.5%	-$2.3M-32.5%	-$1.7M+12.9%	-$2.0M-1344.6%	$157K+3.3%	$152K	$0	$0
Net Income	-$51.9M	-$108.0M-36.7%	-$79.0M+10.2%	-$88.0M+38.9%	-$144.0M-1700.0%	-$8.0M-291.8%	$4.2M-47.9%	$8.0M+203.3%	$2.6M+766.7%	-$396K+93.6%	-$6.1M-142.3%	-$2.5M-323.9%	$1.1M-44.3%	$2.0M+3027.7%	$65K+105.5%	-$1.2M
EPS (Basic)	N/A	-$0.84-35.5%	-$0.62+11.4%	-$0.70+39.7%	-$1.16-1557.1%	-$0.07-275.0%	$0.04-50.0%	$0.08+14.3%	$0.07+150.0%	-$0.14+65.0%	-$0.40-900.0%	-$0.04-300.0%	$0.02-50.0%	$0.04	$0.00+100.0%	-$0.03
EPS (Diluted)	-$0.39	-$0.84-35.5%	-$0.62+11.4%	-$0.70+39.7%	-$1.16-1557.1%	-$0.07-275.0%	$0.04-50.0%	$0.08	$0.07	-$0.14	-$0.40	-$0.04-300.0%	$0.02-50.0%	$0.04	$0.00+100.0%	-$0.03
Diluted Shares (Avg)	N/A	128M+1.1%	127M+0.9%	126M+1.0%	124M+3.5%	120M+7.3%	112M+7.9%	104M	92M	79M	78M	61M+8.1%	56M+6.1%	53M+8.3%	49M+13.9%	43M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$201.7M+11.2%	$186.7M+11.1%	$190.2M+10.6%	$187.8M+11.9%	$181.3M+10.2%	$168.0M+7.5%	$172.0M+10.6%	$167.8M+10.4%
Cost of Revenue	$109.8M+5.5%	$105.8M+11.6%	$106.8M+12.8%	$107.4M+15.5%	$104.1M+13.1%	$94.8M+4.4%	$94.7M+7.7%	$92.9M+3.7%
Gross Profit	$91.9M+18.9%	$80.9M+10.4%	$83.3M+7.9%	$80.4M+7.4%	$77.3M+6.6%	$73.2M+11.9%	$77.3M+14.3%	$74.9M+20.2%
R&D Expenses	$10.8M+19.3%	$9.5M-6.4%	$9.2M+15.2%	$8.7M+13.1%	$9.0M+14.4%	$10.2M+33.6%	$8.0M+11.8%	$7.7M+45.4%
SG&A Expenses	$63.6M-11.3%	$65.7M-3.6%	$63.5M-0.2%	$69.9M+4.3%	$71.7M+13.3%	$68.2M+3.7%	$63.6M+6.5%	$67.0M+8.9%
Operating Income	-$9.8M+79.5%	-$18.2M+34.4%	-$13.4M+27.1%	-$27.0M-27.4%	-$47.6M-117.1%	-$27.8M+9.0%	-$18.4M+0.9%	-$21.2M+12.4%
EBITDA	$6.4M+121.2%	-$1.8M+81.9%	$3.0M+1499.5%	-$10.6M-229.3%	-$30.4M-692.0%	-$10.1M+17.9%	-$213K0.0%	-$3.2M+47.0%
Interest Expense	$781K-16.3%	$598K-63.0%	$599K-63.1%	$603K-63.3%	$933K-44.0%	$1.6M-4.0%	$1.6M-84.6%	$1.6M+157.8%
Income Tax	-$412K+43.1%	-$472K-277.4%	-$2.5M-214.1%	$740K+593.3%	-$724K-93.1%	$266K+142.9%	-$804K+16.3%	-$150K+94.9%
Net Income	$2.2M+105.0%	-$17.1M+34.0%	-$9.9M+36.8%	-$27.1M-53.3%	-$45.1M-141.9%	-$25.9M+4.2%	-$15.6M-8.6%	-$17.7M+4.4%
EPS (Basic)	$0.02+105.7%	-$0.13+35.0%	-$0.07+41.7%	-$0.21-50.0%	-$0.35-133.3%	-$0.20+4.8%	-$0.12-9.1%	-$0.14+6.7%
EPS (Diluted)	$0.02+105.7%	-$0.13+35.0%	-$0.07+41.7%	-$0.21-50.0%	-$0.35-133.3%	-$0.20+4.8%	-$0.12-9.1%	-$0.14+6.7%
Diluted Shares (Avg)	131M+2.3%	129M+1.4%	N/A	128M+1.2%	128M+1.2%	127M+1.0%	N/A	127M+1.0%

NEO Balance Sheet

NEO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.4B-17.0%	$1.6B-2.6%	$1.7B-3.4%	$1.7B-6.9%	$1.9B+89.2%	$988.3M+39.3%	$709.5M+40.5%	$505.0M+46.6%	$344.5M+2.2%	$337.1M-4.0%	$351.3M+333.1%	$81.1M+103.2%	$39.9M+32.7%	$30.1M+50.7%	$19.9M
Current Assets	$376.3M-36.9%	$596.0M-0.1%	$596.8M-1.4%	$605.3M-11.2%	$681.5M+51.9%	$448.7M+54.3%	$290.7M+180.5%	$103.7M+20.7%	$85.9M+8.9%	$78.8M-4.3%	$82.4M+40.2%	$58.7M+113.7%	$27.5M+48.0%	$18.6M+41.0%	$13.2M
Cash & Equivalents	$159.6M-56.5%	$367.0M+7.2%	$342.5M+30.1%	$263.2M-16.9%	$316.8M+38.5%	$228.7M+32.2%	$173.0M+1663.5%	$9.8M-23.5%	$12.8M+2.4%	$12.5M-46.5%	$23.4M-30.5%	$33.7M+596.9%	$4.8M+158.8%	$1.9M-28.9%	$2.6M
Short-Term Investments	$0-100.0%	$19.8M-72.7%	$72.7M-58.4%	$174.8M-12.0%	$198.6M+194.0%	$67.5M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$28.6M+6.8%	$26.7M+10.7%	$24.2M-0.5%	$24.3M+3.8%	$23.4M-20.8%	$29.5M+105.0%	$14.4M+66.5%	$8.7M+15.7%	$7.5M+19.5%	$6.3M+22.4%	$5.1M+95.3%	$2.6M+13.7%	$2.3M+23.8%	$1.9M+54.7%	$1.2M
Accounts Receivable	$159.2M+5.8%	$150.5M+14.7%	$131.2M+9.6%	$119.7M+6.8%	$112.1M+4.9%	$106.8M+13.4%	$94.2M+22.5%	$76.9M+27.3%	$60.4M+8.9%	$55.5M+13.4%	$48.9M+139.0%	$20.5M+9.8%	$18.7M+32.9%	$14.0M+77.8%	$7.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$524.3M+0.3%	$522.8M0.0%	$522.8M0.0%	$522.8M-0.8%	$527.1M+149.7%	$211.1M+6.3%	$198.6M+0.4%	$197.9M+34.6%	$147.0M0.0%	$147.0M0.0%	$147.0M+4919.4%	$2.9M	N/A	N/A	N/A
Total Liabilities	$523.3M-28.9%	$735.7M-0.5%	$739.7M-0.3%	$742.0M-2.6%	$761.5M+159.0%	$294.0M+45.5%	$202.1M+9.5%	$184.6M+32.0%	$139.9M-7.1%	$150.5M+33.0%	$113.2M+446.7%	$20.7M+13.7%	$18.2M-12.7%	$20.9M+48.4%	$14.1M
Current Liabilities	$88.3M-70.7%	$301.2M+212.8%	$96.3M+7.1%	$89.9M+3.1%	$87.2M+19.2%	$73.2M+14.5%	$63.9M+4.9%	$60.9M+67.1%	$36.5M-4.3%	$38.1M-4.9%	$40.1M+173.9%	$14.6M+2.1%	$14.3M-19.3%	$17.8M+55.2%	$11.4M
Non-Current Liabilities	$435.0M+0.1%	$434.5M-32.5%	$643.4M-1.3%	$652.1M-3.3%	$674.3M+205.3%	$220.9M+59.8%	$138.2M+11.8%	$123.6M+19.6%	$103.4M-8.0%	$112.4M+53.7%	$73.1M+1103.0%	$6.1M+56.6%	$3.9M+25.3%	$3.1M+18.8%	$2.6M
Long-Term Debt	$341.9M+0.4%	$340.3M-36.8%	$538.2M+0.5%	$535.3M+0.5%	$532.6M+215.0%	$169.1M+77.9%	$95.0M+2.3%	$92.9M+1.9%	$91.1M-0.9%	$91.9M+75.7%	$52.3M	N/A	$3.3M	N/A	N/A
Total Equity	$836.6M-7.3%	$902.3M-4.2%	$941.5M-5.7%	$998.0M-9.9%	$1.1B+59.6%	$694.3M+36.8%	$507.4M+58.3%	$320.4M+86.3%	$172.0M+5.9%	$162.3M-22.2%	$208.5M+245.2%	$60.4M+178.2%	$21.7M+135.6%	$9.2M+56.3%	$5.9M
Retained Earnings	-$433.8M-33.2%	-$325.8M-31.9%	-$247.1M-55.3%	-$159.1M-972.2%	-$14.8M-106.5%	-$7.2M+36.7%	-$11.4M+41.3%	-$19.4M+66.9%	-$58.4M-11.4%	-$52.5M-137.8%	-$22.1M-13.7%	-$19.4M+5.5%	-$20.5M+9.0%	-$22.6M+0.3%	-$22.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.4B-3.0%	$1.3B-15.9%	$1.4B-17.0%	$1.4B-16.2%	$1.4B-15.2%	$1.6B-2.4%	$1.6B-2.6%	$1.6B-2.2%
Current Assets	$381.5M-2.8%	$373.7M-34.9%	$376.3M-36.9%	$382.5M-35.2%	$392.6M-32.8%	$573.9M0.0%	$596.0M-0.1%	$590.2M+0.6%
Cash & Equivalents	$145.5M-5.9%	$146.1M-57.8%	$159.6M-56.5%	$164.1M-54.7%	$154.7M-56.4%	$346.2M+4.3%	$367.0M+7.2%	$362.0M+18.2%
Short-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$9.0M-72.7%	$11.9M-77.5%	$19.8M-72.7%	$25.8M-73.1%
Inventory	$27.1M-20.6%	$29.8M+0.2%	$28.6M+6.8%	$28.5M+16.4%	$34.2M+47.2%	$29.8M+46.5%	$26.7M+10.7%	$24.5M+1.7%
Accounts Receivable	$175.4M+14.6%	$167.4M+10.7%	$159.2M+5.8%	$155.3M+2.6%	$153.1M+4.5%	$151.2M+7.8%	$150.5M+14.7%	$151.4M+14.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$524.0M0.0%	$524.0M+0.2%	$524.3M+0.3%	$524.3M+0.3%	$524.1M+0.3%	$522.8M0.0%	$522.8M0.0%	$522.8M0.0%
Total Liabilities	$566.5M+4.9%	$517.8M-27.4%	$523.3M-28.9%	$536.5M-26.8%	$539.9M-25.8%	$713.2M-0.5%	$735.7M-0.5%	$732.9M+0.3%
Current Liabilities	$105.9M+5.8%	$84.6M-69.8%	$88.3M-70.7%	$97.9M-67.0%	$100.1M-65.5%	$279.7M+264.6%	$301.2M+212.8%	$296.4M+219.0%
Non-Current Liabilities	$460.6M+4.7%	$433.2M-0.1%	$435.0M+0.1%	$438.6M+0.5%	$439.8M+0.5%	$433.5M-32.3%	$434.5M-32.5%	$436.5M-31.6%
Long-Term Debt	$374.2M	N/A	$341.9M+0.4%	N/A	N/A	N/A	$340.3M-36.8%	N/A
Total Equity	$785.7M-8.0%	$828.8M-6.7%	$836.6M-7.3%	$838.3M-7.7%	$854.0M-6.8%	$888.3M-3.8%	$902.3M-4.2%	$908.2M-4.1%
Retained Earnings	-$448.7M-13.1%	-$450.9M-28.2%	-$433.8M-33.2%	-$423.9M-36.5%	-$396.8M-35.5%	-$351.7M-28.3%	-$325.8M-31.9%	-$310.5M-33.4%

NEO Cash Flow Statement

NEO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$22.0M	$5.2M-25.5%	$7.0M+459.6%	-$2.0M+97.0%	-$66.0M-147.0%	-$26.7M-1930.3%	$1.5M-93.8%	$23.4M-47.8%	$44.8M+148.3%	$18.0M-16.0%	$21.5M+235.9%	$6.4M-32.3%	$9.4M+324.3%	$2.2M+552.6%	-$492K-813.0%	$69K
Depreciation & Amortization	N/A	$67.8M-6.5%	$72.5M0.0%	$72.6M+4.5%	$69.4M+30.1%	$53.4M+106.0%	$25.9M+27.3%	$20.3M+28.7%	$15.8M+1.3%	$15.6M-2.1%	$15.9M+136.8%	$6.7M+25.9%	$5.3M+27.6%	$4.2M+15.2%	$3.6M+74.4%	$2.1M
Stock-Based Compensation	N/A	$41.3M+23.7%	$33.4M+35.6%	$24.6M-0.2%	$24.7M+9.9%	$22.5M+119.9%	$10.2M+2.1%	$10.0M+43.8%	$7.0M+8.0%	$6.4M+18.4%	$5.4M+56.3%	$3.5M+442.7%	$641K-3.8%	$666K+3.3%	$645K+126.3%	$285K
Capital Expenditures	$29.4M	$27.0M-34.2%	$41.1M+42.8%	$28.8M-6.9%	$30.9M-51.8%	$64.1M+120.4%	$29.1M+45.3%	$20.0M+40.0%	$14.3M+4.5%	$13.7M+81.7%	$7.5M+240.2%	$2.2M-41.3%	$3.8M+87.6%	$2.0M-23.1%	$2.6M+191.5%	$897K
Free Cash Flow	-$7.4M	-$21.8M+36.0%	-$34.0M-10.9%	-$30.7M+68.3%	-$96.9M-6.6%	-$90.9M-228.8%	-$27.6M-927.4%	$3.3M-89.0%	$30.5M+601.1%	$4.3M-68.8%	$13.9M+233.7%	$4.2M-26.4%	$5.7M+2528.7%	$216K+107.0%	-$3.1M-275.2%	-$828K
Investing Cash Flow	-$19.9M	-$12.3M-196.0%	$12.9M-83.2%	$76.7M+14736.9%	$517K+100.1%	-$632.4M-296.6%	-$159.4M-712.2%	-$19.6M+85.9%	-$139.7M-920.4%	-$13.7M	N/A	N/A	N/A	-$2.0M+44.9%	-$3.7M-307.1%	-$897K
Financing Cash Flow	-$11.4M	-$200.3M-4411.0%	$4.6M+2.0%	$4.6M-61.5%	$11.8M-98.4%	$725.3M+207.8%	$235.6M+47.7%	$159.5M+73.4%	$92.0M+2345.6%	-$4.1M	N/A	N/A	N/A	$2.8M-18.7%	$3.4M+43.5%	$2.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$20.0M-1.8%	-$8.1M+67.9%	$1.3M-86.3%	$8.9M-3.9%	$20.3M+46.3%	-$25.3M+2.3%	$9.8M-44.9%	$9.2M+268.2%
Depreciation & Amortization	$16.2M-6.1%	$16.4M-7.4%	$16.4M-9.9%	$16.4M-8.6%	$17.3M-4.7%	$17.7M-3.0%	$18.2M-0.9%	$18.0M-0.8%
Stock-Based Compensation	$8.2M-32.7%	$9.6M-10.4%	N/A	$10.3M	$12.2M+38.2%	$10.8M+38.3%	N/A	$0
Capital Expenditures	$8.2M+30.0%	$5.0M+11.1%	$7.9M-32.1%	$8.3M-23.0%	$6.3M-51.7%	$4.5M-19.4%	$11.6M+64.4%	$10.8M+152.7%
Free Cash Flow	$11.7M-16.2%	-$13.1M+56.0%	-$6.5M-262.9%	$570K+136.7%	$14.0M+1620.8%	-$29.8M+5.3%	-$1.8M-116.8%	-$1.6M+84.1%
Investing Cash Flow	-$8.3M+10.7%	-$5.0M-240.4%	-$6.3M-15.3%	-$277K+92.1%	-$9.3M-227.4%	$3.6M-75.5%	-$5.5M-131.8%	-$3.5M-116.9%
Financing Cash Flow	-$12.2M+94.0%	-$338K-135.6%	$431K-37.3%	$765K-35.0%	-$202.4M-10396.7%	$949K+16.3%	$687K-45.9%	$1.2M-36.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NEO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NEO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	43.2%-0.7pp	43.9%+2.6pp	41.3%+4.5pp	36.9%-1.8pp	38.6%-3.2pp	41.8%-6.3pp	48.1%+2.2pp	46.0%+3.5pp	42.4%+0.1pp	42.3%	N/A	N/A	N/A	N/A	44.7%
Operating Margin	-15.9%-2.0pp	-13.9%+4.3pp	-18.2%+12.7pp	-30.9%-6.4pp	-24.5%-21.4pp	-3.1%-6.3pp	3.2%-0.4pp	3.6%+2.4pp	1.2%+0.3pp	0.9%	-112.7%	44.4%-19.1pp	63.5%+39.3pp	24.2%+25.2pp	-0.9%
Net Margin	-14.8%-2.9pp	-12.0%+2.9pp	-14.9%+13.4pp	-28.2%-26.6pp	-1.7%-2.6pp	0.9%-1.0pp	2.0%+1.0pp	0.9%+1.1pp	-0.2%+2.5pp	-2.6%+48.0pp	-50.7%-73.3pp	22.6%-18.0pp	40.7%+39.4pp	1.3%+4.0pp	-2.7%
Return on Equity	-12.9%-4.1pp	-8.8%+0.6pp	-9.3%+5.1pp	-14.4%-13.7pp	-0.7%-1.3pp	0.6%-1.0pp	1.6%+0.8pp	0.8%+1.1pp	-0.2%+3.6pp	-3.8%-2.6pp	-1.2%-3.1pp	1.9%-7.5pp	9.4%+8.7pp	0.7%+20.7pp	-20.0%
Return on Assets	-7.9%-3.1pp	-4.8%+0.4pp	-5.2%+3.0pp	-8.3%-7.8pp	-0.4%-0.9pp	0.4%-0.7pp	1.1%+0.6pp	0.5%+0.6pp	-0.1%+1.7pp	-1.8%-1.1pp	-0.7%-2.1pp	1.4%-3.7pp	5.1%+4.9pp	0.2%+6.1pp	-5.9%
Current Ratio	4.26+2.3x	1.98-4.2x	6.20-0.5x	6.73-1.1x	7.81+1.7x	6.13+1.6x	4.55+2.8x	1.70-0.7x	2.35+0.3x	2.070.0x	2.06-2.0x	4.02+2.1x	1.92+0.9x	1.05-0.1x	1.15
Debt-to-Equity	0.410.0x	0.38-0.2x	0.570.0x	0.54+0.1x	0.48+0.2x	0.24+0.1x	0.19-0.1x	0.29-0.2x	0.530.0x	0.57+0.3x	0.25-0.1x	0.34+0.2x	0.15-2.1x	2.26-0.1x	2.38
Asset Turnover	0.53+0.1x	0.40+0.1x	0.35+0.1x	0.290.0x	0.26-0.2x	0.45-0.1x	0.580.0x	0.55-0.1x	0.700.0x	0.69+0.7x	0.010.0x	0.06-0.1x	0.130.0x	0.17-2.0x	2.18
FCF Margin	-3.0%+2.2pp	-5.1%0.0pp	-5.2%+13.8pp	-19.0%-0.3pp	-18.8%-12.5pp	-6.2%-7.0pp	0.8%-10.2pp	11.0%+9.2pp	1.8%-4.2pp	6.0%-77.5pp	83.6%	113.6%	4.3%+66.5pp	-62.1%-60.2pp	-1.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	45.6%+3.0pp	43.3%-0.3pp	43.8%-1.1pp	42.8%-1.8pp	42.6%-1.5pp	43.6%+1.7pp	44.9%+1.5pp	44.6%+3.6pp
Operating Margin	-4.9%+21.4pp	-9.8%+6.8pp	-7.0%+3.7pp	-14.4%-1.8pp	-26.3%-12.9pp	-16.6%+3.0pp	-10.7%+1.2pp	-12.6%+3.3pp
Net Margin	1.1%+26.0pp	-9.2%+6.3pp	-5.2%+3.9pp	-14.4%-3.9pp	-24.9%-13.5pp	-15.4%+1.9pp	-9.1%+0.2pp	-10.5%+1.6pp
Return on Equity	0.3%+5.6pp	-2.1%+0.9pp	-1.2%+0.6pp	-3.2%-1.3pp	-5.3%-3.2pp	-2.9%0.0pp	-1.7%-0.2pp	-1.9%0.0pp
Return on Assets	0.2%+3.4pp	-1.3%+0.3pp	-0.7%+0.2pp	-2.0%-0.9pp	-3.2%-2.1pp	-1.6%0.0pp	-0.9%-0.1pp	-1.1%0.0pp
Current Ratio	3.60-0.3x	4.42+2.4x	4.26+2.3x	3.91+1.9x	3.92+1.9x	2.05-5.4x	1.98-4.2x	1.99-4.3x
Debt-to-Equity	0.48-0.2x	0.62-0.2x	0.410.0x	0.64-0.2x	0.63-0.2x	0.800.0x	0.38-0.2x	0.810.0x
Asset Turnover	0.150.0x	0.140.0x	0.140.0x	0.140.0x	0.130.0x	0.100.0x	0.100.0x	0.100.0x
FCF Margin	5.8%-1.9pp	-7.0%+10.7pp	-3.4%-2.4pp	0.3%+1.2pp	7.7%+7.2pp	-17.8%+2.4pp	-1.1%-8.0pp	-0.9%+5.5pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
NeoGenomics, Inc. NEO	FY2025	$727.3M	-$108.0M	-14.8%	$2.2B	51/100
Neogen Corp NEOG	FY2026	$870.4M	-$7.9M	-0.9%	$2.6B	27/100
Opko Health OPK	FY2025	$606.9M	N/A	N/A	$1.1B	40/100
Fulgent Genetics FLGT	FY2025	$322.7M	-$60.5M	-18.8%	$553.6M	44/100
Grail Inc GRAL	FY2025	$147.2M	-$408.4M	N/A	$3.5B	62/100
Caredx CDNA	FY2025	$379.8M	-$21.4M	-5.6%	$2.6B	43/100

Where NeoGenomics, Inc. Ranks

Frequently Asked Questions

What is NeoGenomics, Inc.'s annual revenue?

NeoGenomics, Inc. (NEO) reported $727.3M in total revenue for fiscal year 2025. This represents a 10.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NeoGenomics, Inc.'s revenue growing?

NeoGenomics, Inc. (NEO) revenue grew by 10.1% year-over-year, from $660.6M to $727.3M in fiscal year 2025.

Is NeoGenomics, Inc. profitable?

No, NeoGenomics, Inc. (NEO) reported a net income of -$108.0M in fiscal year 2025, with a net profit margin of -14.8%.

What is NeoGenomics, Inc.'s EBITDA?

NeoGenomics, Inc. (NEO) had EBITDA of -$48.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does NeoGenomics, Inc. have?

As of fiscal year 2025, NeoGenomics, Inc. (NEO) had $159.6M in cash and equivalents against $341.9M in long-term debt.

What is NeoGenomics, Inc.'s gross margin?

NeoGenomics, Inc. (NEO) had a gross margin of 43.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is NeoGenomics, Inc.'s operating margin?

NeoGenomics, Inc. (NEO) had an operating margin of -15.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is NeoGenomics, Inc.'s net profit margin?

NeoGenomics, Inc. (NEO) had a net profit margin of -14.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is NeoGenomics, Inc.'s return on equity (ROE)?

NeoGenomics, Inc. (NEO) has a return on equity of -12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NeoGenomics, Inc.'s free cash flow?

NeoGenomics, Inc. (NEO) recorded an outflow of $21.8M in free cash flow during fiscal year 2025. This represents a 36.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NeoGenomics, Inc.'s operating cash flow?

NeoGenomics, Inc. (NEO) generated $5.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NeoGenomics, Inc.'s total assets?

NeoGenomics, Inc. (NEO) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are NeoGenomics, Inc.'s capital expenditures?

NeoGenomics, Inc. (NEO) invested $27.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does NeoGenomics, Inc. spend on research and development?

NeoGenomics, Inc. (NEO) invested $37.1M in research and development during fiscal year 2025.

How many shares does NeoGenomics, Inc. have outstanding?

NeoGenomics, Inc. (NEO) had 130M shares outstanding as of fiscal year 2025.

What is NeoGenomics, Inc.'s current ratio?

NeoGenomics, Inc. (NEO) had a current ratio of 4.26 as of fiscal year 2025, which is generally considered healthy.

What is NeoGenomics, Inc.'s debt-to-equity ratio?

NeoGenomics, Inc. (NEO) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NeoGenomics, Inc.'s return on assets (ROA)?

NeoGenomics, Inc. (NEO) had a return on assets of -7.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NeoGenomics, Inc.'s P/E ratio?

NeoGenomics, Inc. (NEO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.2B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NeoGenomics, Inc.'s price-to-sales ratio?

NeoGenomics, Inc. (NEO) trades at 2.9x sales, its market capitalization divided by revenue of $766.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.2B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NeoGenomics, Inc.'s Altman Z-Score?

NeoGenomics, Inc. (NEO) has an Altman Z-Score of 2.61, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is NeoGenomics, Inc.'s Piotroski F-Score?

NeoGenomics, Inc. (NEO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NeoGenomics, Inc.'s earnings high quality?

NeoGenomics, Inc. (NEO) reported a net loss of $108.0M while generating $5.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NeoGenomics, Inc. cover its interest payments?

NeoGenomics, Inc. (NEO) reported an operating loss of $115.9M against $3.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is NeoGenomics, Inc.?

NeoGenomics, Inc. (NEO) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.